Literature DB >> 21374075

The mechanisms of cancer immunoescape and development of overcoming strategies.

Tomonori Yaguchi1, Hidetoshi Sumimoto2, Chie Kudo-Saito2, Nobuo Tsukamoto2, Ryo Ueda2, Tomoko Iwata-Kajihara2, Hiroshi Nishio2,3, Naoshi Kawamura2, Yutaka Kawakami2.   

Abstract

Cancer-induced immunosuppression is a major problem as it reduces the anti-tumor effects of immunotherapies. In cancer tissues, cancer cells, immune cells, and other stromal cells interact and create an immunosuppressive microenvironment through a variety of immunosuppressive factors. Some cancer subpopulations such as cancer cells undergoing epithelial-mesenchymal transition and cancer stem-like cells have immunosuppressive and immunoresistant properties. The production of immunosuppressive factors by cancer cells is mechanistically attributed to oncogenic signals frequently activated in cancer cells, including the STAT3, MAPK, NF-κB, and Wnt/β-catenin signals, which are upstream events leading to immunosuppressive cascades. Moreover, some of these signals are also activated in immunosuppressive immune cells stimulated by cancer-derived factors and contribute to their immunosuppressive activities. Therefore, targeting these signals both in cancer cells and immunosuppressive immune cells may result in the restoration of immunocompetence in cancer patients and improve current immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21374075     DOI: 10.1007/s12185-011-0799-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  54 in total

1.  CD200 as a prognostic factor in acute myeloid leukaemia.

Authors:  A Tonks; R Hills; P White; B Rosie; K I Mills; A K Burnett; R L Darley
Journal:  Leukemia       Date:  2007-01-25       Impact factor: 11.528

Review 2.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 4.  Tumor-stromal cell interactions and opportunities for therapeutic intervention.

Authors:  Taturo Udagawa; Mark Wood
Journal:  Curr Opin Pharmacol       Date:  2010-07-16       Impact factor: 5.547

5.  CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.

Authors:  Martin Augsten; Christina Hägglöf; Eleonor Olsson; Claudia Stolz; Panagiotis Tsagozis; Tetyana Levchenko; Mitchell J Frederick; Ake Borg; Patrick Micke; Lars Egevad; Arne Ostman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

6.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 7.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

8.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

Authors:  Madeleine M Hipp; Norbert Hilf; Steffen Walter; Daniela Werth; Katharina M Brauer; Markus P Radsak; Toni Weinschenk; Harpreet Singh-Jasuja; Peter Brossart
Journal:  Blood       Date:  2008-02-29       Impact factor: 22.113

9.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

View more
  46 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 2.  Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.

Authors:  Ester Simeone; Antonio M Grimaldi; Paolo A Ascierto
Journal:  Melanoma Manag       Date:  2015-02-25

3.  Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.

Authors:  Kui S Voo; Laura Bover; Megan L Harline; Long T Vien; Valeria Facchinetti; Kazuhiko Arima; Larry W Kwak; Yong J Liu
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

4.  Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.

Authors:  Ausilia Sellitto; Gennaro Galizia; Umberto De Fanis; Eva Lieto; Anna Zamboli; Michele Orditura; Ferdinando De Vita; Riccardo Giunta; Giacomo Lucivero; Ciro Romano
Journal:  J Clin Immunol       Date:  2011-09-14       Impact factor: 8.317

5.  Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.

Authors:  Daniel W Vermeer; William C Spanos; Paola D Vermeer; Annie M Bruns; Kimberly M Lee; John H Lee
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

6.  Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.

Authors:  Kui Shin Voo; Laura Bover; Megan Lundell Harline; Jinsheng Weng; Naoshi Sugimoto; Yong-Jun Liu
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

7.  Injectable, Tough Alginate Cryogels as Cancer Vaccines.

Authors:  Ting-Yu Shih; Serena O Blacklow; Aileen W Li; Benjamin R Freedman; Sidi Bencherif; Sandeep T Koshy; Max C Darnell; David J Mooney
Journal:  Adv Healthc Mater       Date:  2018-02-14       Impact factor: 9.933

Review 8.  Immunosuppressive cells in tumor immune escape and metastasis.

Authors:  Yang Liu; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2015-12-22       Impact factor: 4.599

9.  Prognostic Significance of the Immunological Indices in Patients Who Underwent Complete Resection of Pulmonary Metastases of Colorectal Cancer.

Authors:  Yuki Okazaki; Masatsune Shibutani; E N Wang; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Shinichiro Kashiwagi; Hiroaki Tanaka; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 10.  Regulatory T cells in inflammatory bowel diseases and colorectal cancer.

Authors:  Györgyi Műzes; Béla Molnár; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.